(Q35208413)

7 August 2017

1 reference

title

The safety of SSRIs in generalised anxiety disorder: any reason to be anxious? (English)

1 reference

7 August 2017

1 reference

Prakash S Masand

1

1 reference

7 August 2017

Sanjay Gupta

series ordinal

2

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

Expert Opinion on Drug Safety

7 August 2017

published in

1 reference

7 August 2017

volume

2

1 reference

7 August 2017

issue

5

1 reference

7 August 2017

page(s)

485-493

1 reference

Generalised anxiety disorder: treatment options

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

Clinically significant drug interactions with antidepressants in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

21 January 2018

Biological Perspectives

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

Combined psychoeducation and treatment with selective serotonin reuptake inhibitors for youth with generalized social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

Citalopram in pregnancy and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

Treatment of generalized anxiety disorder with citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

Treatment of social anxiety disorder with citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.5.485

21 January 2018

Identifiers

DOI

10.1517/14740338.2.5.485

1 reference

7 August 2017

1 reference